Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Caribou Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Caribou Biosciences, Inc.

CRBU

Caribou Biosciences, Inc.

About Caribou Biosciences, Inc.

Caribou Biosciences is a biopharmaceutical company specializing in CRISPR-based genome editing to develop allogeneic cell therapies. Its core focus is on off-the-shelf CAR-T treatments for hematologic cancers and autoimmune diseases, utilizing proprietary chRDNA technology for precise, multiplex genome modifications. The company aims to enhance therapy durability, safety, and accessibility through innovative gene editing, targeting unmet medical needs in oncology and immunology markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Caribou Biosciences, Inc.

1
1
Caribou Biosciences, Inc. Caribou Biosciences Reports $25.1 Million Net Loss in Q1 2026, Improved from $40 Million Loss in Q1 2025

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Caribou Biosciences, Inc. Caribou Biosciences Reports $148.1 Million Net Loss and Revenue Growth to $11.2 Million in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Caribou Biosciences, Inc. Caribou Biosciences Reports $27.5 Million Net Loss in Q3 2025, Revenue Increases to $2.2 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Caribou Biosciences, Inc. Caribou Biosciences Reports $54.1 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Caribou Biosciences, Inc. Caribou Biosciences Reports $39.99 Million Net Loss in Q1 2025, Announces Workforce Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Caribou Biosciences, Inc. Caribou Biosciences Reports $149.1 Million Net Loss for 2024, Decreased Revenue and Increased Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Caribou Biosciences, Inc. Caribou Biosciences Reports Significant Financial Decline, Net Loss Widens in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments